clinical trial · NCT05458102
Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels
Gilead Sciences·phase1·terminated·n = 18
Human Immunodeficiency Virus Type 1 (HIV-1) InfectionVesatolimodCobicistatVoriconazoleRifabutin
brief summary
The goal of this clinical study is to learn more about the impact of cobicistat (COBI) (P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and strong cytochrome P450 enzyme \[CYP\]3A inhibitor), voriconazole (VOR) (strong CYP3A inhibitor), and rifabutin (RFB) (moderate CYP3A inducer) on the study drug, vesatolimod (VES), in people with HIV-1 on antiretroviral therapy (ART).
started
Aug 19, 2022
primary completion
May 1, 2023
completion
May 1, 2023
last updated
Dec 3, 2024
official title
A Phase 1, Open-label, Multicohort Study to Evaluate the Impact of Inhibitors and Inducers of Cytochrome P450 Enzyme (CYP)3A and/or P-glycoprotein (P-gp) on the Pharmacokinetics (PK) of Vesatolimod (VES) in Virologically Suppressed Adults With HIV-1 on Antiretroviral Therapy (ART)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol